PMID- 30597767
OWN - NLM
STAT- MEDLINE
DCOM- 20200303
LR  - 20200303
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 9
IP  - 5
DP  - 2019 May
TI  - Semaphorin 3A inhibits allergic inflammation by regulating immune responses in a 
      mouse model of allergic rhinitis.
PG  - 528-537
LID - 10.1002/alr.22274 [doi]
AB  - BACKGROUND: It has been reported that semaphorin 3A (sema3A) could improve 
      allergic symptoms in allergic rhinitis (AR) mice. However, the immunomodulatory 
      roles of sema3A in AR remain unclear. This study was performed to determine the 
      immunoregulatory effects of sema3A on airway inflammation in an AR mice model. 
      METHODS: First, sema3A expression was measured in the serum of AR patients and 
      also in a mice model. Then, nasal symptoms, ovalbumin (OVA)-specific 
      immunoglobulin E (IgE) production, cytokine levels, and histologic structure were 
      analyzed in OVA-sensitized mice, sema3A mice, mice given saline, and controls. 
      The percentages of CD4(+) IL-4(+) IFN-gamma(-) Th2 cells, CD4(+) IFN-gamma(+) IL-4(-) Th1 
      cells, CD4(+) IL-17(+) Th17 cells, and CD4(+) CD25(+) Foxp3(+) Treg cells in the 
      spleen were also analyzed. RESULTS: Serum sema3A levels in both AR patients and 
      OVA-sensitized mice decreased significantly compared with controls. The 
      intranasal administration of sema3A reduced allergic symptom scores, eosinophil 
      infiltration, and OVA-specific IgE production in OVA-sensitized mice. In 
      addition, levels of IL-4 and IL-17 as well as percentages of CD4(+) IL-17(+) Th17 
      cells were suppressed by sema3A administration. Levels of IFN-gamma and IL-10 and 
      ratios of CD4(+) IFN-gamma(+) IL-4(-) Th1/CD4(+) IL-4(+) IFN-gamma(-) Th2 cells, as well 
      as percentages of CD4(+) CD25(+) Foxp3(+) Treg cells, were increased by 
      administration of sema3A. CONCLUSION: Our results demonstrate that sema3A 
      suppressed allergic inflammation in AR via inhibition of Th2/Th17 responses and 
      enhancement of Th1/Treg responses.
CI  - (c) 2018 ARS-AAOA, LLC.
FAU - Xiang, Rong
AU  - Xiang R
AD  - Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, China.
FAU - Xu, Yu
AU  - Xu Y
AD  - Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, China.
AD  - Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of 
      Wuhan University, Wuhan, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, China.
AD  - Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of 
      Wuhan University, Wuhan, China.
FAU - Kong, Yong-Gang
AU  - Kong YG
AD  - Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, China.
AD  - Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of 
      Wuhan University, Wuhan, China.
FAU - Tan, Lu
AU  - Tan L
AD  - Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, China.
FAU - Chen, Shi-Ming
AU  - Chen SM
AD  - Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, China.
AD  - Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of 
      Wuhan University, Wuhan, China.
FAU - Deng, Yu-Qin
AU  - Deng YQ
AD  - Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, China.
AD  - Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of 
      Wuhan University, Wuhan, China.
FAU - Tao, Ze-Zhang
AU  - Tao ZZ
AD  - Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, China.
AD  - Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of 
      Wuhan University, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181231
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Allergens)
RN  - 0 (Cytokines)
RN  - 0 (Immunologic Factors)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Semaphorin-3A)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Adult
MH  - Allergens/immunology
MH  - Animals
MH  - Cytokines/blood
MH  - Disease Models, Animal
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Immunologic Factors/*blood/pharmacology
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Ovalbumin/immunology
MH  - Recombinant Proteins/pharmacology
MH  - Rhinitis, Allergic/blood/*immunology
MH  - Semaphorin-3A/*blood/pharmacology
MH  - T-Lymphocytes/immunology
MH  - Young Adult
OTO - NOTNLM
OT  - T lymphocytes
OT  - allergic reactions
OT  - cytokines
OT  - immune system
OT  - nasal mucosa
OT  - regulatory
EDAT- 2019/01/01 06:00
MHDA- 2020/03/04 06:00
CRDT- 2019/01/01 06:00
PHST- 2018/07/02 00:00 [received]
PHST- 2018/12/01 00:00 [revised]
PHST- 2018/12/06 00:00 [accepted]
PHST- 2019/01/01 06:00 [pubmed]
PHST- 2020/03/04 06:00 [medline]
PHST- 2019/01/01 06:00 [entrez]
AID - 10.1002/alr.22274 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2019 May;9(5):528-537. doi: 10.1002/alr.22274. Epub 
      2018 Dec 31.